Safety and Efficacy of ActiGraft Treatment in Wound Care in Medical Centers

NCT04699305 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-07-29

No results posted yet for this study

Summary

Multicenter observational study to explore the efficacy of ActiGraft in the treatment of exuding cutaneous wounds in real-life usage.

Conditions

  • Cutaneous Wounds

Interventions

DEVICE

ActiGraft

Whole blood clot (WBC) gel

Sponsors & Collaborators

  • RedDress Ltd.

    lead INDUSTRY

Principal Investigators

  • Sharon Sirota · RedDress Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-14
Primary Completion
2026-07-01
Completion
2027-01-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04699305 on ClinicalTrials.gov